Opus Genetics (IRD) announced that its work was featured on Good Morning America in honor of World Blindness Awareness Month. The feature highlighted the story of Lindsey Rambo, the second participant in Opus Genetics’ ongoing Phase 1/2 trial of gene therapy OPGx-LCA5, aimed at restoring vision for people living with a rare genetic form of blindness caused by mutations in the LCA5 gene, which encodes lebercilin, a protein essential for photoreceptor structure.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Wedbush starts Opus with Outperform on gene therapy potential
- Opus Genetics initiated with an Outperform at Wedbush
- Opus Genetics’ New Study on Vision Improvement: What Investors Need to Know
- Opus Genetics Advances Genetic Therapy for Rare Eye Conditions
- Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update